Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Journal of Translational Medicine

Figure 4

From: Identification of novel epitopes from human papillomavirus type 18 E7 that can sensitize PBMCs of multiple HLA class I against human cervical cancer

Figure 4

Cervical cancer cell cytotoxicity of PBMCs sensitized with HPV 18 E7 81-95 (#21) and E7 89-103 (#23) peptides. Cytotoxicity assays with HLA-matched cervix cancer cell lines were tested using the 51Cr-release assay to confirmed HPV18 E781-95 (#21)- and E789-103 (#23)-sensitized PBMCs could successfully recognized same peptides that naturally presented on the surface of cancer cells. E781-95 (#21)- and E789-103 (#23)-sensitized PBMCs of HLA-A*02:01 and HLA-A*24:02 lysed greater quantities of HTB-34 cells (HPV 18+, HLA-A*02:01) (A) and SNU-1160 (HPV 18+, HLA-A*24:02) (B) than that of negative control (PBMCs sensitized with no peptide), respectively. Data are representative of at least three independent experiments using PBMCs from HLA-A*02:01, HLA-A*24:02, HLA-A*11:01, HLA-A*33:03 subjects. Data are presented as mean (point) ± standard error (bar).

Back to article page